Emerging technologies reshape pharma outsourcing, experts say

WEST SUSSEX, UNITED KINGDOM — In the rapidly evolving pharmaceutical industry, emerging technologies are reshaping the landscape of outsourcing partner evaluations.
In an exclusive interview with Outsourcing Pharma, industry experts from software solutions provider CluePoints, including Francois Torche, Steve Young, and Patrick Hughes, shared their insights on how artificial intelligence (AI) and machine learning are revolutionizing drug development and clinical trials.
AI-driven innovation in drug development
Focusing on product development, CluePoints Chief Product & Technology Officer Francois Torche emphasized the transformative power of AI and machine learning in drug development. These technologies enable more efficient data analysis and predictive modeling, significantly reducing the time and cost associated with identifying potential drug candidates.
CluePoints is at the forefront of this innovation, particularly in Risk-Based Quality Management (RBQM) and centralized monitoring. Their advanced data analytics platform leverages AI to identify and mitigate risks in clinical trials, ensuring prompt issue resolution and improved trial efficiency.
The future of personalized medicine
Torche predicts that the next notable advancements will come from the integration of multi-omics data and the application of AI in personalized medicine.
This approach promises to improve treatment efficacy and minimize adverse effects, ultimately leading to better patient outcomes.
Enhancing clinical trial quality through RBQM
Focusing on regulations and the TUFTS activity, CluePoints Chief Scientific Officer Steve Young highlighted the latest evidence demonstrating the effectiveness of RBQM in improving clinical trial quality.
Recent studies have shown significant reductions in protocol deviations and data inconsistencies in trials implementing RBQM.
Despite the broad acknowledgment of RBQM’s benefits, Young noted that practical challenges such as resource constraints and lack of expertise hinder widespread adoption.
However, he predicts that in five years, RBQM practices will be more integrated into clinical trial management, with standardized protocols and best practices emerging.
Making AI insights actionable
Meanwhile, CluePoints Chief Commercial Officer Patrick Hughes, focusing on branding and the industry landscape, explained the firm’s new brand narrative: “turning artificial intelligence into human intelligence.”
This approach aims to make AI-driven insights accessible and actionable for clients, leading to improved trial efficiencies and better patient outcomes.
Investments fuel future growth
Hughes also discussed the implications of EQT’s investment in CluePoints, which will enable the company to accelerate growth, enhance technological infrastructure, and expand its global footprint.
This investment positions CluePoints to bring more innovative solutions to the market and strengthen its leadership in the RBQM and Risk-Based Data Management (RBDM) space.
These experts’ insights highlight the transformative potential of new methodologies and technologies in the pharmaceutical industry, promising improved evaluation and management of outsourcing partners and driving innovation in clinical trials.